Abstracts Highlight Progress in the Fight Against
Kidney Cancer - GU ASCO 2023
Arpita Desai, MD
University of California San Francisco, San Francisco CA
ABSTRACT
This year’s American Society of Clinical Oncology
Genitourinary Cancers (ASCO GU) Symposium was
held from 16-18 February 2023, in San Francisco, CA
USA. As one of the most renowned conferences focusing
on genitourinary cancers, this symposium brought
together oncology professionals from around the globe
for presentations and discussions surrounding the latest
innovative findings in genitourinary cancer treatment,
research, and care. Here is the summary of some kidney
cancer research presented at the ASCO GU 2023 meeting.
INTRODUCTION
The 2023 ASCO GU Conference brought together
leading experts in the field to share the latest
developments and insights into the diagnosis,
treatment, and management of GU cancers. In this article, we will take a closer look at some of the exciting
and promising findings from the 2023 ASCO GU pertaining to renal cell carcinoma (RCC).
The RCC highlights of this year's conference included the ZIRCON study which evaluated
radiolabeled 89Zr-DFO-girentuximab (a monoclonal
antibody targeting CA IX) for detection of clear cell
RCC in patients with indeterminate renal masses. This
phase III trial included patients with renal masses (≤7
cm, cT1) who were scheduled to undergo a nephrectomy
in 90 days and all patients received a single dose of
Radiolabeled 89Zr-DFO-girentuximab (37 MBq ± 10%;
10 mg girentuximab) on Day 0 and underwent PET/CT
imaging on Day 5 (± 2 days) prior to surgery. The study
met its co-primary end points exceeding the sensitivity
and specificity thresholds and confirmed a favorable
toxicity profile (Shuch, Pantuck et al. 2023). This study
lays the foundation and provides a convenient non-invasive platform for pre-treatment risk stratification
of clear cell RCC akin to PSMA in prostate cancer.
Dr. Choueiri presented an exploratory post
hoc subgroup analysis of KEYNOTE 564 across the
UISS (University of California Los Angeles Integrated
Staging System) risk groups and disease stage. The
Keynote 564 trial showed an improvement in disease
free survival in patients with clear cell RCC with a
high risk of recurrence leading to the FDA approval
of pembrolizumab in the adjuvant setting. The UISS
is a commonly used prognostic model that predicts
the 5-year survival rates following a nephrectomy.
In this trial, most patients in both the arms were
categorized in the UISS intermediate group (75%) with
5.9% of patients having M1NED disease. Up to 88% of
patients had AJCC Stage 3 disease. The results showed
that adjuvant pembrolizumab prolonged disease-free survival across subgroups by AJCC Stage, TNM
staging, Fuhrman grading and UISS risk compared to
placebo. The extent of benefit was most pronounced in
patients with M1NED disease (HR: 0.28, 95% CI: 0.11
– 0.73), AJCC stage 3 (HR: 0.68, 95% CI: 0.51 – 0.89)
and Stage 4 disease (HR: 0.42, 95% CI: 0.20 – 0.87).
This exploratory analysis further supports the use of
pembrolizumab in patients with a high risk of recurrence
in the adjuvant setting (Choueiri, Tomczak et al. 2023).
Dr. Powles presented an updated analysis of
the COSMIC 313 trial which was the first phase 3 trial
exploring the triplet combination of cabozantinib along
with ipilimumab and nivolumab versus ipilimumab
and nivolumab, a contemporary control arm in patients
with advanced RCC with intermediate or poor IMDC
risk. With an additional follow up of 5 months, the
progression free survival (PFS) benefit with the triplet
combination was maintained in the overall population
with a HR of 0.74 (95% CI 0.61-0.90) and HR of 0.68
(95% CI 0.54-0.86) in the intermediate risk population.
Similarly, the objective response rate was also higher
with the triplet combination in the intermediate
risk group compared to the poor risk group. There
were no major differences in the treatment exposure
between both the triplet arms that could explain the
enhanced efficacy in the intermediate risk group
(11.3 months in the intermediate risk population and
10.4 months in the poor risk population). The daily
dose of cabozantinib received was also similar in
both the groups. Adverse events leading to treatment
discontinuation was more common in the intermediate
risk population compared to the poor risk group. It is
important to note that patients in the poor risk group
had significantly fewer nephrectomies compared to the
intermediate risk group (40% and 50% in the triplet
arm and comparator poor risk group compared to 73%
and 69% in the triplet and comparator intermediate
risk group respectively) and this could be one of the
reasons behind the lower response rates in this patient
population. Another likely explanation is that the poor
risk group is biologically more immune driven than
angiogenesis driven compared to the favorable risk
population (Rini, Huseni et al. 2018, Tannir, Signoretti
et al. 2021). Overall survival follow up in ongoing
(Powles, Motzer et al. 2023) and will be important to
consider for regulatory approval of this combination
in intermediate and poor risk IMDC risk groups.
Treatment free survival is a meaningful clinical
end point that has not been traditionally evaluated
as a predefined end point in clinical trials. Dr. Atkins
presented the updated analysis of treatment free
survival of HCRN GU16-260-Cohort A (Atkins, Jegede
et al. 2023). In this study, 128 patients with advanced
clear cell RCC received treatment with nivolumab
and based on their response they received additional
treatment with nivolumab for up to 96 weeks if they
had a partial response or a complete response or salvage
ipilimumab was added if they had progressive disease or
stable disease at 48 weeks. Treatment free survival was
defined as the area between the Kaplan Meier curves for
time from registration to stopping protocol therapy and
time from registration to starting subsequent therapy or
death estimated at a mean of 36 months. The response
rate in the favorable risk group was 57.9% with the
overall response rates being 35.9% at 3 years, 65.6% of
patients with favorable risk were alive and treatment
free compared to 27.1% of patients with intermediate/
poor risk disease. The overall PFS was 14.6%. The 36
month mean treatment free survival was 36% in the
favorable risk group which included 4% of patients with
TRAE >3 and the treatment free survival was 22% in
the intermediate/poor risk group which included 3% of
patients with TRAE >3. Based on this study, salvage ipi/
nivo in is a viable option in patients who do not respond
to nivolumab monotherapy in the front line setting
and has a robust treatment free survival with limited
toxicity. The maximum benefit was obtained by the
favorable risk group like the DFS benefit in favorable
risk group in the Checkmate 214 trial supporting the use
of this regimen in favorable risk patients (45% vs 36%)
Dr. Albiges presented to interim results of
CaboPoint which is a phase II study of cabozantinib in
adults with advanced clear cell RCC with progressive
disease after front line checkpoint inhibitor therapy.
The study consisted of two cohorts: Cohort A including
patients with progressive disease after ipilimumab
and nivolumab and cohort B including patients with
progressive disease on immunotherapy and a VEGFR
TKI. Most patients had intermediate risk disease
with upfront metastatic disease and did not have a
nephrectomy. The ORR in cohort A was 31.7% (95%
CI, 20.3-45) and Cohort B was 25% (95% CI, 10.7-44.9).
Cabozantinib was effective as a second line treatment
option irrespective of the front-line regimen used, with
patients with intermediate risk disease having failed
ipilimumab and nivolumab seemed to benefit the most
with a RR of 40%. The duration of front line therapy
also had an impact with patients benefitting more if
they received cabozantinib in the primary refractory
setting having had progressive disease within 6 months
of front line therapy (Albiges, Powles et al. 2023).
The updated results of the BIONIKK trials were
also presented (Vano, Phan et al. 2023). This was a
randomized phase II trial that prospectively selected
patients to receive either nivolumab, nivolumabipilimumab or a VEGRF TKI based on the tumor
molecular group. They had previously reported high
efficacy of VEGFR TKI in CCRCC2 tumors (51%) and
high efficacy of nivolumab with ipilimumab in CCRC4
(50%) compared to CCRC1 (39%) tumors. After a
follow up of 46.5 months, the median overall survival
was not reached for ipilimumab /nivolumab and was
35 months for nivolumab (HR compared to nivo/ipi:
1.56, 95% CI: 0.99 to 2.46) and 45 months for VEGFR
TKI (HR compared to nivo/ipi: 1.29, 95% CI: 0.76 to
2.19). When the overall survival was characterized by
molecular group, superior survival was observed with
the ipilimumab/nivolumab combination compared
to nivolumab alone in CCRC1 (HR: 1.44) and CCRC4
(HR: 1.64) groups. There was no difference in survival
with treatment with either VEGFR TKI or ipilimumab/
nivolumab in the CCRC2 (HR: 1.15) group. About 80%
of patients went on to receive second line treatment
and most of them received a VEGFR TKI (79%).
After a median follow up of 34 months, there was a
higher response rate after ipilimumab and nivolumab
(33%) than after single agent nivolumab (11%) in the
CCRC4 group and the CCRC2 group has the highest
response rate of 62% post ipilimumab and nivolumab
and 57% post VEGRF TKI. The updated results
confirmed the feasibility of biomarker driven trials
in RCC and the efficacy of ipililumab/nivolumab in
CCRC4 and VEGFR TKI in CCRC2 molecular groups.
Dr. Siva reviewed the use of radiation in oligometastatic
kidney cancer. The ASCO guidelines include
radiotherapy for management of patients with low
volume metastatic disease (Rathmell, Rumble et al.
2022) . In a meta-analysis of 28 studies including 1600
patients with almost 4000 treated lesions, the local
control rate for both intra cranial and extracranial
lesions was 90%. Prospective trials of radiation
in oligometastatic RCC have shown that SABR
(stereotactic ablative radiation) can be effectively
delivered in lieu of systemic therapy. In a single center
study of 30 patients with low burden of disease (having
1 median number of metastases) with a median follow
up of 17.5 months, the one-year progression free
survival was 64%, the median progression free survival
was 23 months and importantly, at one year, 82% of
patients did not receive any systemic therapy (Tang,
Msaouel et al. 2021) . Radiation can also be used in
the oligoprogressive setting to prolong the efficacy of
systemic therapy.
In a
multicenter trial of 37 patients with oligoprogressive
disease, SABR to the oligoprogressive sites resulted
in a 93% one-year disease control rate and a
progression free survival of 9.3 months. SABR can
also be safely delivered with immunotherapy. In the
RAPPORT trial, patients received a combination
of six months of pembrolizumab with SABR taking
advantage of the synergy between radiotherapy and
immunotherapy inducing tumor antigen and cytokine
release by radiotherapy which can prime the tumor
microenvironment and likely transform a cold to
hot microenvironment. The median progression
free survival was 15 months, and the two-year local
control rate was 92% (Siva, Bressel et al. 2022) .
SABR therefore, provides a safe, non-invasive option
of prolonging the efficacy of systemic therapy and has
synergy with immunotherapy
*
Arpita Desai, MD
University of California San Francisco, San Francisco CA